ECHO-7 Oncolytic virotherapy for UVEAL Melanoma
Solution for unmet medical need

Dedicated Spinoff from RIGVIR holding – an independent biotech Company with its own trademark for the product

Medical Need

- UVEAL Melanoma is an orphan (rear) disease. About 50% of the patients develop metastases, with the liver being the most frequent site. For these patients 1-year survival is reported to be 15%
- There is no standard treatment available

Objective

- Execution of clinical trials and consecutive registration of medicine – as a treatment for UVEAL MELANOMA cancer - in Europe (EMA region)

Market

- There are 46,179 uvea melanoma patients in EU28. Incidence – 3,929 per year
- Target Market value at least 200 Million EUR annually
- Annual target price of treatment – eventual 25,000 EUR.
- Plus Other Non EU Market potentials

Advantages

- Commercialized active substance ECHO7 from established GMP manufacturer
- ECHO7 is first registered and the only non-genetically modified oncolytic virotherapy
- Safe, effective and well tolerated solution with long-term clinical application
- Ready for Proof of Concept Phase II study
- Encouraging preclinical results
- Real clinical application and sound clinical observations
- Full set of IPR

EMA support

- Market exclusivity in the EU
- Accelerated registration and evaluation
- Protocol assistance,
- Fee reductions & EU-funded research

Team

- Complete project management team with comprehensive experience using Oncolytic Virotherapy: business development; scientific; clinical and regulatory expertise

Investment Opportunity A:

- EUR 1.2 million
- Lead investor
- Goal: Team; Validation of biomarkers; finalization of Clinical trial protocol and registration roadmap; processing of scientific data and EMA advice
- Time - Up-to 18 Months
- Exit: B-level investment

Investment Opportunity B:

- ~ EUR 10 million
- LiveScience /biotech investor,
- Goal: Team; Execution of clinical trials; registration in EU (EMA);
- Time – 3-4 years
- Exit: Sale to Big-Pharma or out-licensing

development@rigvir.com